Traditional solid-phase array and
alternative bead array are some of the types of DNA microarray. Major
applications of DNA/Gene microarray include, genomics, gene expression, Single
Nucleotide Polymorphism (SNP) analysis, and proteomics.
The global DNA/Gene
Microarray Market is estimated to account for US$ 3,018.3 Mn in terms of
value in 2020 and is expected to reach US$ 7,693.0 Mn by the end of 2027.
Global DNA/Gene Microarray
Market: Drivers
Significant developments in
personalized medicines is expected to fuel growth of the global DNA/gene
microarray market over the forecast period. For instance, in April 2020,
Indivumed GmbH, an oncology company, launched the Oncology Alliance for
Individualized Medicine, an international collaborative alliance to advance
personalized medicine in cancer through IndivuType, the company’s multi-omics
database.
Global DNA/Gene Microarray
Market: Opportunities
Increasing investment in DNA
sequencing is expected to offer lucrative growth opportunities for players in
the market. For instance, in January 2020, Element Biosciences, a biotechnology
startup, raised US$ 80 million to develop DNA sequencing platform.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/3825
Global DNA/Gene Microarray
Market: Restraints
Presence of alternative
technologies is expected to hamper growth of the global DNA/gene microarray
market. Protein chip and lab-on-chip, glycomic arrays, tissue arrays, and cell
arrays are some of the alternatives to DNA/gene microarray.
Key Takeaways:
The global DNA/gene microarray
market was valued at US$ 2,640.7 Mn in 2019 and is forecast to reach a value of
US$ 7,693.0 Mn by 2027 at a CAGR of 12.4% between 2020 and 2027. The market is
expected to witness significant growth owing to increasing technological
advancement in microarray technology, and increasing demand for genetic
testing.
Gene expression and SNP analysis
segment held dominant position in the global DNA/gene microarray market in
2019, accounting for 25.6% share in terms of value, followed by oncology and
drug development, respectively. Increasing drug development, and demand for
personalized medicine is expected to support growth of the segment over the
forecast period.
North America held dominant
position in the global DNA/gene microarray market in 2019, accounting for 34.1%
share in terms of value, followed by Europe and Asia Pacific, respectively.
North America has presence of leading manufacturers, and wide number of
research institutes which make use of these products. These factors are
expected to support growth of the market over the forecast period.
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/dna-gene-microarray-market-3825
Market Trends
The market is witnessing launch
of new genetic tests. For instance, in July 2019, MyHeritage, an online
genealogy platform with web, mobile, and software products and services,
launched new Health+Ancestry test, a health-related genetic test.
The market is also witnessing
increasing adoption of nanoarrays, owing to their various advantages in terms
of sensitivity, specificity, speed, portability, throughput, and cost.
Nanoarrays find application in drug discovery and disease diagnosis.
Global DNA/Gene Microarray Market:
Competitive Landscape
Major players operating in the global
DNA/gene microarray market include, Affymetrix, Inc., Illumina, Inc., Agilent
Technologies Inc., Roche NimbleGen Inc., Sequenom, Inc., Biometrix Technology
Inc., LC Sciences, Life Technologies Corp., Lifegen Technologies LLC,
Microarrays Inc.
Global DNA/Gene Microarray
Market: Key Developments
Major players in the market are
focused on launching new products to expand their product portfolio. For
instance, in February 2020, Twist Bioscience Corporation launched the Twist
Targeted Methylation Sequencing Solution to study methylation pattern changes
in a wide range of research fields including cancer
Major players in the market are
also focused on adopting M&A strategies to expand their product portfolio.
For instance, in December 2019, Oncology Pharma, Inc. signed a Letter of Intent
to acquire at least a 50% stake in Diagnomics, Inc., a private CLIA certified
& CAP accredited private molecular Genomics lab and provider of DNA
microarrays, Next Generation Sequencing, and real-time PCR solutions
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/3825
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment